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Abstract 
 
 Background 
Many patients in primary care stop antidepressant treatment after only one prescription, so do not 
benefit from treatment. Some patients who stop initial antidepressant treatment go on to restart it, but 
neither the incidence of restarting, nor the probability that patients who restart treatment subsequently 
complete an adequate course of treatment is known.  
Methods 
We used a primary care database (over 1.2 million records) to study patients who commenced 
treatment with an eligible antidepressant between April 2007 and March 2008 and who stopped 
treatment for at least one month after the first prescription. We examined their subsequent 
antidepressant prescriptions to estimate the probability of restarting antidepressant treatment, the 
likelihood of continuing subsequent treatment, and the patient characteristics associated with these. 
Results 
6,952/24,817 (28%) patients discontinued antidepressant treatment after the first prescription. The 
cumulative probability of restarting treatment after early discontinuation was 8.6% (95% ci 8.0 - 9.3) 
after one month off treatment, and 24.1% (22.9 - 25.2) after 9 months off treatment. The probability of 
those who restarted treatment continuing for 6 months or more was 29.3% (26.5 -32.5).   
Conclusions 
Few patients who stop antidepressant treatment after the first prescription subsequently complete an 
adequate treatment course within the next year. Initiatives to promote adherence to appropriate 
antidepressant treatment should begin during the first prescription.  
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 Introduction 
Guidelines for treatment of depression recommend antidepressants for depression of at least 
moderate severity and that this treatment should be continued for ≥6 months following symptom 
resolution 1,2.  In routine care, much antidepressant treatment is not guideline-compliant and around a 
quarter of patients prescribed a new antidepressant stop after the first prescription  3-5. There are 
several possible reasons for early discontinuation including disagreement between doctor and patient 
over the diagnosis or the appropriateness of pharmacotherapy  6-9.  Qualitative research has 
suggested that early discontinuation may be followed by sustained treatment, as patients 
“experiment” with treatment before committing to a full course  10. However we could find no 
quantitative data on subsequent use of antidepressants after early discontinuation, although other 
studies have examined longer timescales 11. Studies on antidepressant adherence have generally 
considered the first interruption in treatment as cessation of treatment and the endpoint for the study  
3,4. 
 We carried out a primary care database study to investigate (a) how many patients who stopped an 
antidepressant prescription after one month went on to restart over the next 10 months, (b) how long 
the subgroup of patients who restarted continued their treatment, and (c) how these behaviours 
related to patient characteristics. 
 
Methods 
We analysed data from the Primary Care Clinical Informatics Unit Research (PCCIUR) database, 
comprising anonymised information from General Practices across Scotland.  We extracted data on 
all prescriptions for included antidepressants between 1 April 2006 and 31 March 2008 and 
demographic details of patients who received them.  
We included adults continuously registered with the same GP practice throughout the study period 
who began a new course of an eligible antidepressant in the months of April 2007 to March 2008 (i.e. 
after at least one year without antidepressant treatment). Eligible antidepressants were those 
 
 commonly used in primary care to treat depression: serotonin-specific reuptake inhibitors (SSRIs); 
serotonin noradrenaline reuptake inhibitors (SNRIs; except duloxetine), lofepramine and trazodone.  
We excluded patients <18 years and patients whose only prescription was in the final month of the 
time period as it was impossible to assess discontinuation after this. We used calendar months as the 
unit of analysis for treatment and for each patient we categorised each month with a binary value of 1 
(“on-treatment”) or 0 (“off-treatment”). Patients’ treatment over the two years of data could thus be 
summarised by a sequence of 24 binary digits.  The process of condensing the detailed prescription 
information into this sequence began by calculating the number of days of treatment in each 
prescription using details of the prescriptions (date, dose, frequency and quantities). This detailed 
information allowed the algorithm to handle prescriptions which were shorter or longer than 28 or 30 
days and to differentiate between consecutive prescriptions of the same drug (treatment days were 
added together) and parallel prescription of antidepressants in combination (treatment days were not 
added together).  
We developed a categorisation algorithm to reduce raw data into binary sequences over several 
iterations which led to rules in the algorithm, such as for carrying forward days of treatment, described 
below. For each iteration we checked the output sequence against manual interpretation of the 
prescription data using actual dates. For example the algorithm output sequence “1001” should 
correspond to two periods of treatment separated by at least 60 days without treatment. This 
validation process was conducted on the output from the algorithm of 150 randomly selected records. 
The process of algorithm development and validation continued over several iterations until there was 
full agreement between researchers and the computer algorithm 
The categorisation algorithm is shown as a flow chart in figure 1. It was run for each patient 
separately. For each month in sequence, its external inputs were information about days and dates of 
treatment and its output was a binary value indicating the status of the month as on- or off-treatment. 
Within each month, treatment days prescribed in the month were allocated to that month, except 
where treatment was initiated  (i.e. not a follow-on prescription) after the 21st of a month in which case 
those treatment days were all allocated to the next month. If there were more treatment days 
allocated to a month than days in that month, the left-over treatment days were carried forward to the 
 
 next month. Months containing 4 or more days of treatment were designated on-treatment months (to 
prevent small carry-forward events accounting for extra months on- treatment).  
For analysis, patients were split by sex, age band (18-34,35-64,65 and over) and deprivation, 
calculated using the Carstairs and Morris Index of Deprivation12 and presented as quartiles (quartile 
1=least deprived, quartile 4=most deprived). Patients were classed as ‘early discontinuers’ if their first 
on-treatment month was followed by one or more off-treatment months. Early discontinuers who 
received a subsequent prescription for an antidepressant were classed as ‘restarters’. Restarters 
could either be returning for treatment of the index depressive episode or consulting about a new 
episode after a period of wellbeing.  These could not be differentiated using the available data. For 
each restarter, we calculated the time between the initial single prescription and the restart, the 
duration of the restarted treatment, and the total number of discrete episodes of treatment. The 
maximum duration of follow up was 10 months (one year minus one month on-treatment and one 
month off- treatment).   
We reported crude rates of restarting after early discontinuation and used odds ratios to examine the 
effects of sex, age and deprivation on these.  We examined the time to restart and the duration of 
restarted treatment using survival analysis in which Cox Proportional Hazards models were adjusted 
for age, sex and deprivation and clustered by GP practice. All statistical analyses were performed 
using R-3.0.1.  
 
  
 
 Results 
Treatment initiation and early discontinuation 
The sample population comprised 1,280,840 patients.  A new eligible course of antidepressant 
treatment was begun by 24,817 adult patients in the study period of whom 16,613 (66.9%) were 
female. 6877 (27.7%) patients were aged 18-34 years, 13,854 (55.8%) 35-64 years and 4086 (16.4%) 
≥65 years;  7560 (30.4%) were in the least deprived quartile, quartile 2: 8,103 (32.7%), quartile 3: 
4,345 (17.5%) and quartile 4: 4,809 (19.4%). 6952 patients prescribed a new course of 
antidepressant were classed as early discontinuers (28%) and of these 1459 (21%) were classed as 
restarters.  Table 1 section A reports the associations of sex, age and deprivation on early 
discontinuation among all patients prescribed a new course of antidepressant.  
Restarting treatment following early discontinuation 
Table 1 section B reports the asoociations of sex, age and deprivation on restarting following early 
discontinuation. Restarting appeared to be slightly more common in patients with greater soci-
economic deprivation. Most patients who restarted antidepressant treatment after early 
discontinuation did so after only one or two months off-treatment: the cumulative probability of 
restarting treatment after early discontinuation was 8.6% (95% ci 8.0 - 9.3) after one off-treatment 
month, 16.1% (15.2 - 17.0) after a further two months, 21.0% (19.9 – 22.0) by 6 months after initially 
stopping treatment  and 24.1% (22.9 - 25.2) by 9 months.  
Duration of restarted treatment 
Survival analysis showed that persistence on restarted antidepressants was poor: only 51.5% (48.9 - 
54.2) of restarters continued treatment beyond 2 months of restarted treatment , and 29.3% (26.5 - 
32.5%) continued beyond 6 months of restarted treatment.  Table 1 section C shows the association 
of duration of treatment with age, sex and deprivation: older patients who restarted treatment were 
most likely to continue restarted treatment and those aged under 35 least likely. Repeatedly cycling 
on and off antidepressants appeared to be uncommon with only 19% of restarters having more than 2 
distinct periods on-treatment. However as data was available for only a maximum of 10 months after 
restarting, this is likely to have been under-identified and  longer periods of follow up are needed to 
obtain acccurate assessments of the prevalence of this behaviour. 
 
 Influence of GP coding of depression 
In view of the relatively low rates of restarting treatment we conducted a post-hoc analysis in which 
we compared those patients whose treatment initation was accompanied with a new diagnostic code 
for depression and those where it was not. We had previously shown that discontinuation after one 
prescription was slightly more common in those without a code 4. By 6 months after the initial 
discontinuation 24.5% (22.3 – 26.7) of those with a code had restarted treatment compared to 18.2% 
(17.1 – 19.2) of those without: hazard ratio 1.41 (1.25 to 1.59). There was no difference in the 
duration of restarted treatment: hazard ratio 0.96 (0.82 to1.12). Data were incomplete for coding 
analysis in 95 cases.  
Discussion 
Summary of main findings 
Patients who receive a single prescription for antidepressants and then discontinue treatment are 
unlikely to restart treatment in the following 12 months. For those who do, particularly when aged 
under 35, the probability of sustained, guideline-compliant, treatment is low.  Repeatedly cycling on 
and off antidepressants is relatively uncommon in all patient groups.   
Strengths and limitations 
We used detailed prescription data from a large and representative database of patients and general 
practices in Scotland to categorise sequential months as on- or off- antidepressant treatment.  This 
gave a measure of patient treatment times and patterns which was validated manually in a random 
sample.   We did not limit the analysis to patients with a coded diagnosis of depression: while this 
means we may have included some patients with other indications for treatment we chose this 
approach because GPs frequently manage depression without electronically recording a diagnostic 
code and we have previously found that uncoded patients were only slightly more likely to discontinue 
treatment 4. While most patients for whom GPs prescribe an antidepressant are appropriately treated 
13, GPs over-diagnose depression in patients with emotional distress. 14,15  Although some patients 
with these conditions may also warrant treatment because of  concurrent anxiety or a history of 
previous depressive episodes 15. Even among patients in whom the GP recorded a code for 
 
 depression, we found that only a quarter had received further antidepressant treatment in the next 6 
months after early discontinuation. 
We limited any effect of prescribing for other indication by excluding antidepressants more commonly 
prescribed for chronic pain (amitriptyline, duloxetine) from our eligible list.  
Antidepressant treatment data were available for one 12 month period only, while this means that the 
number of patients for whom 6 months of data after restarting were available was small, we used 
survival analysis to allow for different durations of follow up. Analysis took place more than 5 years 
after treatment. It used the period of widest coverage of the database, which subsequently reduced in 
size owing to GP system changes. While antidepressant prescribing volumes continue to rise, rates of 
new antidepressant prescribing in Scotland were relatively static around the time of this study 16 and 
there has been only a modest change in the incidence of depression in the UK since then. 17 The 
increased volume of antidepressant prescribing over time has been largely attributed to patients using 
these medications long term 16,18. We are not aware of any substantial changes in rates of 
discontinuation of newly initiated treatment since this data was collected, 
We were unable to link data on treatment discontinuation to clinical outcomes. We previously found 
that self-report measures of depression severity were coded in only a third of new instances of 
depression treatment  4.and many patients who discontinue treatment also discontinue follow up. It is 
not possible to say from our data what proportion of early discontinuers remained depressed.  
Implications for practice 
While our findings do not contradict the suggestion that some patients go through a system of trial 
and error in relation to antidepressant treatment to manage their depression  10, they suggest that it is 
relatively uncommon. Rather, most very short courses of antidepressants are not repeated, 
suggesting either that they were a crisis response  19 or unwanted by the patient  6,8,9. Age, sex and 
deprivation had only small or no associations with restarting or continuing treatment.  
Clinicians, particularly in primary care need to be aware of these patterns in antidepressant use.. For 
patients with clear indications for therapy, they should consider using motivational techniques  20-22, 
structured patient follow up 23, and assessment of treatment preferences 24, in the early stages of  
 
 treatment, to ensure patients stay on the medication for long enough to benefit. For patients where 
there is more uncertainty about the indications of treatment, knowledge of the low probability of 
completing treatment should strengthen practitioners in following guidelines to avoid or defer 
antidepressant prescription. 
Conclusions 
Few patients who stop antidepressant treatment after the first prescription subsequently complete an 
adequate treatment course within the next year. Initiatives to promote adherence to appropriate 
antidepressant treatment need to begin during the first prescription.  
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 Table 1:Influences of patient sex, age and deprivation on probabilities of early discontinuation, restarting treatment and continuing with restarted 
antidepressant treatment during 12 months of follow up in a primary care database population 
Patient 
Characteristics 
A. Number and probability of stopping 
after first prescription 
 
B. Number and probability of 
restarting after discontinuation 
C. Probability of continuing 
restarted treatment 
 
N (%) ORb 95% CI 
 
N (%) HRc 95% CI 
 
HRd 95%CI 
Sex                    
Female 4,647 (28.0) --- a 
  
979 (21.1) --- a 
  
--- a 
 
Male 2,305 (28.1) 1.01 0.95 - 1.07 
 
480 (20.8) 1.01 0.90 - 1.12 
 
0.99 0.86 - 1.14 
Age band 
          
18 – 34 2,263 (32.9) --- a 
  
467 (20.6) --- a 
  
--- a 
 
35 – 64 3,480 (25.1) 0.68 0.64 - 0.73 
 
731 (21.0) 1.02 0.90 - 1.41 
 
1.30 1.12 - 1.50 
65 and older 1,209 (29.5) 0.86 0.79 - 0.93 
 
261 (21.5) 1.06 0.91 - 1.23 
 
1.67 1.35 - 2.06 
Deprivatione 
          
Quartile 1 1,908 (25.2) --- a 
  
383 (20.1) --- a 
  
--- a 
 
Quartile 2 2,322 (25.2) 1.19 1.11 - 1.28 
 
477 (20.5) 1.03 0.89 - 1.19 
 
0.82 0.68 - 0.99 
Quartile 3 1,250 (28.8) 1.20 1.10 - 1.30 
 
253 (20.2) 1.03 0.84 - 1.18 
 
0.81 0.66 - 1.00 
Quartile 4 1,472 (30.6) 1.31 1.21 - 1.42   346 (23.5) 1.19 1.02 - 1.41   0.91 0.74 - 1.11 
Total  6,952       1,459      
a First value in each patient characteristic category set as a reference value. 
b An Odds Ratio of >1 indicates the patient is more likely to discontinue medication after a single month of treatment;  
c HR: hazard ratio.  A hazard ratio >1 indicates the patient is more likely to restart treatment after early discontinuation. 
d HR: hazard ratio.  A hazard ratio >1 indicates the patient is more likely to remain on treatment after restart 
e Deprivation quartiles:  1= least deprived, 4 = most deprived 
 
  
 
 
